MARY OBRIEN: Open Payments
NPI 1740970359 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,122 in 78 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $136 · 2025 $1,122
Food & beverage: $1,122
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $377 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 39 | $314 |
| Otsuka America Pharmaceutical, Inc. | 11 | $205 |
| Janssen Pharmaceuticals, Inc | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Corium, LLC | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: VRAYLAR, CAPLYTA, REXULTI, SPRAVATO, Auvelity, Azstarys, TRINTELLIX, Xelstrym.
Industry payments across OK — which companies pay providers there.
